Digital Symptom Monitoring for Breast Cancer

This trial aims to help women with early-stage hormone receptor-positive breast cancer manage side effects from hormone therapy using a digital tool. Participants will either use a web-based symptom monitoring system (Digital Endocrine Therapy Symptom Monitoring and Education Intervention) or receive standard educational materials. The researchers aim to determine how effectively these tools help women adhere to their prescribed hormone treatments. Women who have recently started hormone therapy and have access to an internet-enabled phone may be suitable candidates for this study. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance the quality of life for future patients.

The trial does not specify if you need to stop taking your current medications, but it does require you to continue your hormone therapy. Other treatments like radiotherapy and certain targeted therapies are allowed.

Research has shown that using digital tools to monitor symptoms in patients receiving hormone therapy for breast cancer is generally safe. Studies have found that these tools, such as apps for tracking symptoms remotely, are easy for patients to use. No major side effects have been reported from these digital systems. They help patients track symptoms and improve communication with healthcare providers, leading to better management of any side effects from hormone therapy. Overall, these tools support patients without adding extra risks.¹²³⁴⁵

Researchers are excited about the Digital Endocrine Therapy Symptom Monitoring and Education Intervention because it introduces a novel way of managing symptoms through digital technology. Unlike traditional treatments that focus solely on medication, this intervention uses a web-based platform to actively monitor and educate patients about their symptoms. This approach empowers patients by providing real-time feedback and personalized education, potentially leading to better adherence to treatment and improved quality of life. Additionally, this method promotes patient engagement and self-management, which are crucial for long-term health outcomes.

Research has shown that digital tools for tracking symptoms can assist individuals undergoing hormone therapy for breast cancer. In this trial, participants in ARM A will use a web-based symptom monitoring intervention. One study found that a symptom-tracking app improved quality of life and helped manage symptoms, even if it didn't affect medication adherence. Another study found that app-based tools reduced cancer-related symptoms, which can complicate daily life. Feedback from app users indicated they missed fewer doses and managed symptoms more actively. This evidence suggests that digital tools may help patients handle side effects and maintain their treatment regimen. Participants in ARM B will receive usual care, including an educational handout on endocrine therapy.⁶⁷⁸⁹¹⁰